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Introduction
The Vel blood group antigen was first described in 1952 when a 
Vel– patient with anti-Vel developed an acute intravascular hemo-
lytic reaction after transfusion of Vel+ red cells [1]. After further re-
ports of acute hemolytic transfusion reactions and hemolytic disease 
of newborns of Vel– mothers, Vel was recognized as a clinically im-
portant blood group antigen [2, 3]. The exact immunogenicity of the 
Vel antigen is not known but there are several requests and nation-
wide searches for Vel– red cell concentrates every year in Germany. 
According to the report of the ISBT Working Party on Rare Donors, 
Vel– blood is one of the most difficult to obtain blood types in sev-
eral countries (‘Global Definitions of Rare Donors’, WP Meeting 
ISBT Congress 2013, Amsterdam). Because of the clinical signifi-
cance of anti-Vel that mostly leads to severe complement-mediated 
intravascular hemolysis, it is important to find enough Vel– blood 
donors. Up to date there are approximately 20–30 known Vel– 
blood donors and about 50 cryopreserved Vel– red cell concentrates 
in Germany. These numbers are not sufficient to provide compatible 
red cell units to all patients with anti-Vel. The prevalence of the Vel– 
blood type was found to be slightly different in the populations, i.e., 
1 in 3,985 British individuals (0.025%), 1 in 2,500 Americans (0.04%) 
and 1 in 1,762 individuals (0.057%) in Sweden [1, 3]. It was specu-
lated whether or not the highest frequency of the Vel– blood type 
can be found in northern Scandinavia.
In 2013 different groups reported the genetic basis of the Vel– 
blood type [4–6]. A 17 bp frame-shift deletion (64–80del) in the 
coding region of the SMIM1 gene was homozygous in all Vel– 
samples. The reduced or weak expression of the Vel antigen was 
associated with a heterozygous 64–80del genotype [4, 5]. The In-
ternational Society of Blood Transfusion (ISBT) Working Party for 
Red Cell Immunogenetics and Blood Group Terminology assigned 
the blood group system name VEL and number 034 and promoted 
Vel from a genetically unresolved blood group antigen (ISBT num-
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Summary
Background: The SMIM1 protein carries the Vel blood 
group antigen, and homozygosity for a 17 bp deletion in 
the coding region of the SMIM1 gene represents the mo-
lecular basis of the Vel– blood group phenotype. We de-
veloped PCR-based methods for typing the SMIM1 17 bp 
(64–80del) gene deletion and performed a molecular 
screening for the Vel– blood type in German blood donors. 
Methods: For SMIM1 genotyping, TaqMan-PCR and PCR-
SSP methods were developed and validated using refer-
ence samples. Both methods were used for screening of 
donors with blood group O from southwestern Germany. 
Heterozygotes and homozygotes for the SMIM1 64–80del 
allele were serologically typed for the Vel blood group an-
tigen. In addition, the rs1175550 SNP in SMIM1 was typed 
and correlated to the results of the phenotyping. Results: 
Both genotyping methods, TaqMan-PCR and PCR-SSP, 
represent reliable methods for the detection of the SMIM1 
64–80del allele. Screening of 10,598 blood group O donors 
revealed 5 individuals homozygous for the deletional al-
lele. They were confirmed Vel– by serological typing. Het-
erozygotes for the 64–80del allele showed different anti-
gen expressions ranging from very weak to regular posi-
tive. Conclusion: Molecular screening of blood donors for 
the Vel– blood type is feasible and avoids the limitations of 
serological typing which might show false-negative results 
with heterozygous individuals. The identification of Vel– 
blood donors significantly contributes to the adequate 
blood supply of patients with anti-Vel. 
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ber 212001) to the new system defined by the SMIM1 locus (anti-
gen number 034001). No other null allele of the SMIM1 gene has 
been reported so far. Thus, molecular screening for the Vel– blood 
could be simply based on the specific detection of the SMIM1 64–
80del allele.
Here, we describe PCR-based methods for genotyping the 17 bp 
deletion in the SMIM1 gene underlying the Vel– blood group phe-
notype. We screened 10,598 blood group O donors for the SMIM1 
64–80del allele and confirmed the Vel– donors to be negative by 
serological testing.
Material and Methods
DNA Samples of Blood Donors
This study was performed in a blood donor cohort from the southwestern 
part of Germany. Donors gave written consent to provide blood samples for 
research purposes, and the use of blood samples for research purposes was ap-
proved by the ethics committee of the Heidelberg University, Medical Faculty 
Mannheim. DNA was isolated from EDTA-anticoagulated blood using a com-
mercial system (QIAamp Blood DNA Mini Kit; Qiagen, Hilden, Germany).
Serological Vel Typing
The serological testing for the Vel antigen was performed using the indirect 
antiglobulin test in the gel technique (ID cards, Bio-Rad Cressier, Switzerland; 
and ScanGel, BioRad, Marnes-la-Coquette, France) using a polyclonal anti-Vel 
serum from an immunized patient. To enhance the reactions bithermal incuba-
tion (15 min at 37 ° C and additional 15 min at room temperature) was applied. 
The gel cards were centrifuged for 10 min at 85 × g and visually inspected for 
the agglutination. The serological testing was followed by re-testing of the phe-
notyped blood using PCR with sequence-specific primers (PCR-SSP) to verify 
the SMIM1 genotype. 
SMIM1 Genotyping
For genotyping the 17 bp deletion in SMIM1 specific for the Vel blood 
group we developed a PCR-SSP and a PCR with fluorescent allele-specific 
TaqMan probes. In addition, a PCR-SSP method was developed for genotyping 
the rs1175550 SNP in SMIM1 that was reported to be associated with expres-
sion levels of the Vel antigen [6]. The sequences of primers and probes are listed 
in table 1. Both methods were validated using phenotyped samples including 
two samples with the Vel– blood group phenotype. 
For PCR-SSP part of the HBB gene (β-globin) was co-amplified as 
an internal control PCR fragment (536 bp) using primers β-glob-F (5ʹ-
GGTTGGCCAATCTACTCCCAGG-3ʹ) and β-glob-R (5ʹ-GCTCACTCAGTG-
TGGCAAAG-3ʹ). Genomic DNA (10–50 ng) was subjected to 10 μl PCR reac-
tions including 1 μmol/l SMIM1wt-F primer (for the SMIM1 wild-type allele) 
or SMIM1del17-F (for the SMIM1 64–80del allele), 1 μmol/l SMIM1-R primer, 
0.2 μmol/l each internal control primer, 10 mmol/l Tris-HCl (pH 8.3), 50 
mmol/l KCl, 1.5 mmol/l MgCl2, 200 μmol/l each dNTP, and 0.5 units Taq DNA 
polymerase (Bioron GmbH, Ludwigshafen, Germany). The cycling conditions 
were: 2 min initial denaturation at 95 ° C, followed by 10 cycles with 20 s dena-
turation at 95 ° C and 1 min annealing/extension at 65 ° C, followed by 20 cycles 
with 20 s denaturation at 95 ° C, 1 min annealing at 61 ° C and 30 s extension at 
72 ° C. Amplification products were separated on 2 % agarose gels containing 
GelRed DNA stain (Biotium, Hayward, CA, USA). Results were documented 
using a UV gel documentation device (UVP Inc., Upland, CA, USA). The same 
protocol was used for the rs1775550 genotyping.
For TaqMan-PCR, 20–50 ng genomic DNA was mixed with 0.9 μmol/l each 
of the SMIM1-F1 and SMIM-R1 primers, 0.2 μmol/l each of the TaqMan 
probes in a final volume of 7.5 μl. After addition of 7.5 μl HotRox mastermix 
(Bioron GmbH) the background fluorescence (pre-read) was detected using a 
RealTime PCR cycler (ABI 7000; Applied Biosystems, Waltham, MA, USA). 
Cycling was performed in a standard PCR cycler using the following program: 
10 min at 95 ° C, 40 cycles with 15 s at 92 ° C and 1 min at 60 ° C. After cycling 
the fluorescence signals were detected in a post-read and allocated with the pre-
read data. Values indicating heterozygous and homozygous del17 alleles were 
determined using reference samples.
Results
Molecular Screening for the Vel– Blood Type
The PCR-SSP and TaqMan-PCR methods revealed the expected 
results from the two Vel– reference samples, i.e., the SMIM1 wild-
type allele was absent, and only the 64–80del allele could be de-
tected. In addition, all samples positive for the Vel antigen were 
homozygous or heterozygous for the SMIM1 wild-type allele. 
Screening for the SMIM1 64–80del allele causing the Vel– phe-
notype by using the PCR-SSP method was performed in a two-step 
procedure (fig. 1). In the first step the DNA samples were analyzed 
only using the primers specific for the 64–80del allele. In the sec-
ond step only the positive DNA samples from the first step were 
re-analyzed using both the primers for the wild-type allele and the 
64–80del allele. Because the TaqMan-PCR method detects both al-
leles simultaneously, it determines the genotype of a DNA sample 
by a single reaction (fig. 2). 
Name Allele specificity Direction Sequence (5’–3’) Amplicon size, bp
PCR-SSP
SMIM1wt-F wild type sense GCAGCAGGGACGGAGTCA 216
SMIM1del-F 64-80del sense GCAGCAGGGACGGAGTCC 199
SMIM1-R SMIM1 antisense CCAAAGGCTGCGGTTTGCTG
rs1175550-F1a major A sense TCAGGGGCTGCAGCCTAGA 160
rs1175550-F1g minor G sense TCAGGGGCTGCAGCCTAGG 160
rs1175550-R1 SMIM1 antisense CTCAGGCCAAGCCCTGACC
TaqMan PCR
SMIM1-F1 SMIM1 sense GCCACGTCCACTATAGTAGG 142/125
SMIM1-R1 SMIM1 antisense GGAGACACCAGCCTGCTATG
SMIM1wt-P wild type sense VIC-CTAGGGGCTGTGTC-MGB*
SMIM1del-P 64-80del sense FAM-ACGGAGTCCAGCACAG-MGB*
*TaqMan probe modifications: FAM, VIC, minor groove binding (MGB).
Table 1. Oligonu-
cleotides for SMIM1 
genotyping
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Both methods were used to screen for 64–80del homozygotes in 
10,598 blood donors (table 2). The observed genotype frequencies 
showed no significant deviation from the Hardy-Weinberg equilib-
rium. However, based on the frequency of the 64–80del allele of 
1.81% (383 of 21,196 SMIM1 alleles analyzed) we would expect a 
prevalence for the homozygous genotype of 1 in 3,063 blood do-
nors in our study cohort. We identified 5 donors (0.05%) with the 
homozygous 64–80del genotype, indicating a prevalence of 1 in 
2,120 donors. 
Vel Phenotyping
Expression of the Vel blood group antigen was determined in 45 
genotyped samples using a gel-based agglutination assay. The phe-
notype was clearly Vel+ in homozygotes for the SMIM1 wild-type 
allele (n = 2) and clearly Vel– in homozygotes for the 64–80del al-
lele (n = 4). Among the 39 SMIM1 heterozygotes, we found a broad 
range of the Vel antigen strength in the agglutination assay (fig. 3). 
Using ID gel cards our anti-Vel serum failed to detect the Vel anti-
gen in 11 of the 39 (28.2%) 64–80del heterozygotes. In the more 
sensitive ScanGel cards all heterozygotes showed at least a very 
weak agglutination. The DNA marker rs1175550 is a SNP (A>G) in 
the non-coding region of the SMIM1 gene and is significantly as-
sociated with weak expression of the Vel antigen [6]. We geno-
typed rs1175550 in the 45 Vel-phenotyped samples and could con-
firm a significantly higher expression of the Vel antigen in carriers 
(n = 5) of the minor G allele of rs1175550 (fig. 3). 
Fig. 1. A Representative results from screening of 96 DNA samples for the 
SMIM1 64–80del allele by using PCR-SSP. Most DNA samples were negative 
because only the internal control fragment (arrow head) was amplified. B Three 
positive DNA samples were re-analyzed using both the primers for the wild-
type allele and the 64–80del allele. One of the three DNA samples was negative 
for the wild-type allele indicating a homozygous 64–80del genotype.
Fig. 2. Representative 
results from screening 
of 94 DNA samples for 
the SMIM1 genotype 
by using TaqMan-PCR. 
The simultaneous de-
tection of the wild-type 
allele in the VIC chan-
nel (X-axis) and the 
64–80del allele in the 
FAM channel (Y-axis) 
enables the discrimina-
tion of the three geno-
types: homozygous 
wild type (circles), hete-
rozygotes (triangles), 
homozygous 64–80del 
(diamonds). NTC = No 
template control.
SMIM1 alleles SMIM1 genotypes Vel phenotype*
wt 64–80del wt het 64–80del Vel+ Vel–
Numbers 20,813 383 10,220 373 5 10,593 5
% 98.19 1.81 96.43 3.52 0.05  99.95 0.05
*Deduced from genotype.
Table 2. Results from Vel genotyping of 10,598 
blood donors
Molecular Screening for Vel– Blood Donors in 
Southwestern Germany
Transfus Med Hemother 2015;42:356–360 359
Discussion
As expected, the wild-type allele of the SMIM1 gene defining 
the Vel blood group antigen was highly prevalent in our study co-
hort of 10,598 blood donors. More than 99.9% of the donors were 
either homozygous or heterozygous for the wild-type allele. In our 
approach using PCR-SSP or TaqMan-PCR the SMIM1 wild-type 
allele was detected by the absence of the 64–80 deletion. We cannot 
exclude other deletions or point mutations; however, no other ge-
netic mechanism for the Vel– blood type than the SMIM1 64–80del 
allele has been reported so far. Therefore, it is most likely that all 
donors in our study homozygous or heterozygous for the SMIM1 
wild-type allele express the Vel antigen. Five donors were homozy-
gous for the 17 bp deletion, and we could confirm their Vel– phe-
notype, except for one donor who was not available for a fresh 
blood sample any more. To the best of our knowledge and based 
on the donor registry data the 5 donors were not related.
The frequency of the SMIM1 64–80del allele of 1.81% in our 
study cohort corresponds to the observations of approximately 
1.6% in other European populations [6, 7]. The highest allele fre-
quencies were reported for Scandinavian countries, e.g. 2.9% in 
Swedish blood donors [5], whereas African blacks and Asian do-
nors revealed allele frequencies of only 0.56 and 0.6%, respectively 
[7]. In all populations, the homozygous 64–80del genotype corre-
lated with the Vel– phenotype.
We found individual differences in the Vel antigen expression 
in donors heterozygous for the 64–80del allele ranging from regu-
lar positive to very weak positive (+/–). In general, phenotyping 
very much depends on the quality of anti-Vel serum and on the 
sensitivity of the test technique. Because anti-Vel sera of immu-
nized patients mostly contain a high IgM fraction, the results in the 
ScanGel cards which were known to be very sensitive for IgM anti-
bodies gave positive reactions with all heterozygous Vel samples 
even though the widely used ID cards were negative with some of 
them. Furthermore, genetic factors such as the rs1175550 SNP in 
the non-coding region of SMIM1 can affect the expression of the 
Vel antigen [6, 7]. We could confirm the association of the minor 
G allele of rs1175550 with a significantly stronger antigen expres-
sion in 5 blood donors, who were presumably compound heterozy-
gous for 64–80del and the rs1175550-G alleles. However, this ad-
ditional genetic factor could not explain all variability in Vel anti-
gen expression of 64–80del heterozygotes.
In summary, the molecular screening for Vel– blood donors can 
be performed by fast and robust PCR methods such as PCR-SSP or 
TaqMan-PCR. It is more reliable than serological screening and 
contributes significantly to supplying compatible blood for patients 
with anti-Vel. In our cohort we found a prevalence of 1 in approxi-
mately 2,000 donors of the Vel– genotype. Because of the signifi-
cant clinical relevance of the Vel antigen, it is highly recommended 
to screen for and to register Vel– blood donors, irrespective of the 
size of the blood bank. Of course, cost issues for molecular or sero-
logical screening need to be considered and balanced against costs 
of cryopreservation and storage of Vel– RBC units. 
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Fig. 3. Serological typing Vel of blood donors heterozygous for the SMIM1 
64–80del allele. A Representative results from phenotyping using an anti-Vel 
patient serum and gel-based agglutination. The same samples were analyzed 
using ID-Cards (upper panel) and ScanGel cards (lower panel). Agglutination 
was categorized from negative (0) to very weak (0.5), weak (1.0), moderate (2.0) 
and regular (3.0) positive. Absence (–) or presence (+) of the minor G-allele of 
the rs1175550 SNP is indicated above. B Summary of the agglutination of 39 
SMIM1 64–80del heterozygous blood donors in the two gel cards and under 
consideration of the rs1175550 genotype. The minor G-allele (genotype AG) 
was found in 5 of the samples, 34 samples were homozygous for the major A-
allele. The G-allele was significantly associated with a stronger agglutination. 
None of the samples were negative in the ScanGel cards indicating a higher sen-
sitivity in Vel phenotyping.
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